Spadin Selectively Antagonizes Arachidonic Acid Activation of TREK-1 Channels
TREK-1 channel activity is a critical regulator of neuronal, cardiac, and smooth muscle physiology and pathology. The antidepressant peptide, spadin, has been proposed to be a TREK-1-specific blocker. Here we sought to examine the mechanism of action underlying spadin inhibition of TREK-1 channels....
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-04-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2020.00434/full |
_version_ | 1818927770553548800 |
---|---|
author | Ruolin Ma Anthony Lewis |
author_facet | Ruolin Ma Anthony Lewis |
author_sort | Ruolin Ma |
collection | DOAJ |
description | TREK-1 channel activity is a critical regulator of neuronal, cardiac, and smooth muscle physiology and pathology. The antidepressant peptide, spadin, has been proposed to be a TREK-1-specific blocker. Here we sought to examine the mechanism of action underlying spadin inhibition of TREK-1 channels. Heterologous expression in Xenopus laevis oocytes and electrophysiological analysis using two-electrode voltage clamp in standard bath solutions was used to characterize the pharmacological profile of wild-type and mutant murine TREK-1 and TREK-2 channels using previously established human K2P activators; arachidonic acid (AA), cis-4,7,10,13,16,19-docosahexaenoic acid (DHA), BL-1249, and cinnamyl-3,4-dihydroxy-α-cyanocinnamate (CDC) and inhibitors; spadin and barium (Ba2+). Mouse TREK-1 and TREK-2 channel currents were both significantly increased by AA, BL-1249, and CDC, similar to their human homologs. Under basal conditions, both TREK-1 and TREK-2 currents were insensitive to application of spadin, but could be blocked by Ba2+. Spadin did not significantly inhibit either TREK-1 or TREK-2 currents either chemically activated by AA, BL-1249, or CDC, or structurally activated via a gating mutation. However, pre-exposure to spadin significantly perturbed the subsequent activation of TREK-1 currents by AA, but not TREK-2. Furthermore, spadin was unable to prevent activation of TREK-1 by BL-1249, CDC, or the related bioactive lipid, DHA. Spadin specifically antagonizes the activation of TREK-1 channels by AA, likely via an allosteric mechanism. Lack of intrinsic activity may explain the absence of clinical side effects during antidepressant therapy. |
first_indexed | 2024-12-20T03:18:18Z |
format | Article |
id | doaj.art-06c1bc6beb7c418cb5754e5e62dfcff9 |
institution | Directory Open Access Journal |
issn | 1663-9812 |
language | English |
last_indexed | 2024-12-20T03:18:18Z |
publishDate | 2020-04-01 |
publisher | Frontiers Media S.A. |
record_format | Article |
series | Frontiers in Pharmacology |
spelling | doaj.art-06c1bc6beb7c418cb5754e5e62dfcff92022-12-21T19:55:16ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-04-011110.3389/fphar.2020.00434519659Spadin Selectively Antagonizes Arachidonic Acid Activation of TREK-1 ChannelsRuolin MaAnthony LewisTREK-1 channel activity is a critical regulator of neuronal, cardiac, and smooth muscle physiology and pathology. The antidepressant peptide, spadin, has been proposed to be a TREK-1-specific blocker. Here we sought to examine the mechanism of action underlying spadin inhibition of TREK-1 channels. Heterologous expression in Xenopus laevis oocytes and electrophysiological analysis using two-electrode voltage clamp in standard bath solutions was used to characterize the pharmacological profile of wild-type and mutant murine TREK-1 and TREK-2 channels using previously established human K2P activators; arachidonic acid (AA), cis-4,7,10,13,16,19-docosahexaenoic acid (DHA), BL-1249, and cinnamyl-3,4-dihydroxy-α-cyanocinnamate (CDC) and inhibitors; spadin and barium (Ba2+). Mouse TREK-1 and TREK-2 channel currents were both significantly increased by AA, BL-1249, and CDC, similar to their human homologs. Under basal conditions, both TREK-1 and TREK-2 currents were insensitive to application of spadin, but could be blocked by Ba2+. Spadin did not significantly inhibit either TREK-1 or TREK-2 currents either chemically activated by AA, BL-1249, or CDC, or structurally activated via a gating mutation. However, pre-exposure to spadin significantly perturbed the subsequent activation of TREK-1 currents by AA, but not TREK-2. Furthermore, spadin was unable to prevent activation of TREK-1 by BL-1249, CDC, or the related bioactive lipid, DHA. Spadin specifically antagonizes the activation of TREK-1 channels by AA, likely via an allosteric mechanism. Lack of intrinsic activity may explain the absence of clinical side effects during antidepressant therapy.https://www.frontiersin.org/article/10.3389/fphar.2020.00434/fullspadinTREK-1TREK-2antagonismarachidonic acid |
spellingShingle | Ruolin Ma Anthony Lewis Spadin Selectively Antagonizes Arachidonic Acid Activation of TREK-1 Channels Frontiers in Pharmacology spadin TREK-1 TREK-2 antagonism arachidonic acid |
title | Spadin Selectively Antagonizes Arachidonic Acid Activation of TREK-1 Channels |
title_full | Spadin Selectively Antagonizes Arachidonic Acid Activation of TREK-1 Channels |
title_fullStr | Spadin Selectively Antagonizes Arachidonic Acid Activation of TREK-1 Channels |
title_full_unstemmed | Spadin Selectively Antagonizes Arachidonic Acid Activation of TREK-1 Channels |
title_short | Spadin Selectively Antagonizes Arachidonic Acid Activation of TREK-1 Channels |
title_sort | spadin selectively antagonizes arachidonic acid activation of trek 1 channels |
topic | spadin TREK-1 TREK-2 antagonism arachidonic acid |
url | https://www.frontiersin.org/article/10.3389/fphar.2020.00434/full |
work_keys_str_mv | AT ruolinma spadinselectivelyantagonizesarachidonicacidactivationoftrek1channels AT anthonylewis spadinselectivelyantagonizesarachidonicacidactivationoftrek1channels |